- Home
- PULM vs NTIP Comparison
PULM vs NTIP Comparison
Compare PULM & NTIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PULM
- NTIP
- Stock Information
- Founded
- PULM 2003
- NTIP 1990
- Country
- PULM United States
- NTIP United States
- Employees
- PULM N/A
- NTIP N/A
- Industry
- PULM Biotechnology: Pharmaceutical Preparations
- NTIP Multi-Sector Companies
- Sector
- PULM Health Care
- NTIP Miscellaneous
- Exchange
- PULM Nasdaq
- NTIP Nasdaq
- Market Cap
- PULM 33.2M
- NTIP 28.6M
- IPO Year
- PULM N/A
- NTIP 1998
- Fundamental
- Price
- PULM $6.41
- NTIP $1.39
- Analyst Decision
- PULM
- NTIP
- Analyst Count
- PULM 0
- NTIP 0
- Target Price
- PULM N/A
- NTIP N/A
- AVG Volume (30 Days)
- PULM 57.4K
- NTIP 27.2K
- Earning Date
- PULM 08-12-2025
- NTIP 08-11-2025
- Dividend Yield
- PULM N/A
- NTIP 7.30%
- EPS Growth
- PULM N/A
- NTIP N/A
- EPS
- PULM N/A
- NTIP N/A
- Revenue
- PULM $1,921,000.00
- NTIP $250,000.00
- Revenue This Year
- PULM N/A
- NTIP N/A
- Revenue Next Year
- PULM $134.88
- NTIP N/A
- P/E Ratio
- PULM N/A
- NTIP N/A
- Revenue Growth
- PULM N/A
- NTIP N/A
- 52 Week Low
- PULM $1.78
- NTIP $1.16
- 52 Week High
- PULM $10.40
- NTIP $1.78
- Technical
- Relative Strength Index (RSI)
- PULM 37.18
- NTIP 60.77
- Support Level
- PULM $6.28
- NTIP $1.27
- Resistance Level
- PULM $6.83
- NTIP $1.42
- Average True Range (ATR)
- PULM 0.35
- NTIP 0.07
- MACD
- PULM -0.07
- NTIP 0.01
- Stochastic Oscillator
- PULM 0.00
- NTIP 65.38
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).
About NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property assets. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.